Literature DB >> 11112432

Inhibitory effects of an antisense oligonucleotide in an experimentally infected mouse model of influenza A virus.

T Mizuta1, M Fujiwara, T Abe, N Miyano-Kurosaki, T Yokota, S Shigeta, H Takaku.   

Abstract

The antiviral effects of a 20-mer antisense phosphorothioate oligonucleotide, PB2-as, on influenza A virus infection in mice were examined and compared to those of PB2-as encapsulated with several cationic liposomes. Intravenous injection of PB2-as, as a complex with DMRIE-C, a cationic liposome, was most effective for prolonging the mean survival time in days (MSDs) and increasing the survival rates of mice infected with the influenza A virus. In addition, the liposomal PB2-as significantly inhibited viral growth in lung tissues. These results suggest that PB2-as encapsulated with DMRIE-C may be active against the influenza A virus infection through the inhibition of virus replication in the mouse lung. Copyright 2000 Academic Press.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11112432     DOI: 10.1006/bbrc.2000.3924

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  3 in total

Review 1.  Newer influenza antivirals, biotherapeutics and combinations.

Authors:  Frederick G Hayden
Journal:  Influenza Other Respir Viruses       Date:  2013-01       Impact factor: 4.380

2.  Inhibition of multiple subtypes of influenza A virus in cell cultures with morpholino oligomers.

Authors:  Qing Ge; Manoj Pastey; Darwyn Kobasa; Piliapan Puthavathana; Christopher Lupfer; Richard K Bestwick; Patrick L Iversen; Jianzhu Chen; David A Stein
Journal:  Antimicrob Agents Chemother       Date:  2006-09-11       Impact factor: 5.191

3.  Safety, tolerability, and pharmacokinetics of radavirsen (AVI-7100), an antisense oligonucleotide targeting influenza a M1/M2 translation.

Authors:  John H Beigel; Jocelyn Voell; Paula Muñoz; Parag Kumar; Kristina M Brooks; Jianbo Zhang; Patrick Iversen; Alison Heald; Michael Wong; Richard T Davey
Journal:  Br J Clin Pharmacol       Date:  2017-09-22       Impact factor: 4.335

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.